Sanofi names Mike Quigley CSO
Plus: Entrada promotes Sethuraman to president of R&D and Colston becomes CEO of CS Genetics
Mike Quigley will become CSO and global head of research at Sanofi (Euronext:SAN; NASDAQ:SNY) on Sept. 30, a company spokesperson confirmed to BioCentury. Most recently, Quigley was president and CEO of a stealth start-up that he co-founded; he previously served as president and CEO of Therini Bio Inc. Frank Nestle, his predecessor, left the pharma in June to become partner and CEO of Deerfield Discovery and Development at Deerfield Management.
Entrada Therapeutics Inc. (NASDAQ:TRDA) promoted Natarajan Sethuraman to CSO from president of R&D. Sethuraman joined the intracellular therapies company as CSO in 2017, after serving as executive director and GlycoFi site head at Merck & Co. Inc. (NYSE:MRK). Entrada is using peptide conjugates to deliver biologic payloads into cells...